POLAREAN IMAGING PLC

Board/Management Information • Nov 5, 2018

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 2568G

Polarean Imaging PLC

05 November 2018

5 November 2018

Polarean Imaging Plc 

("Polarean" or the "Company")

Nominated Adviser Status

Polarean Imaging plc (AIM: POLX), the medical‑imaging technology company, with a proprietary drug‑device combination product for the magnetic resonance imaging (MRI) market, announces that the Company's directors are aware of the proposed merger of its current nominated adviser ("Nomad"), Northland Capital Partners ("Northland") with SP Angel Corporate Finance LLP ("SP Angel"). 

It is the intention of the directors to replace the Company's Nomad role with SP Angel.

The directors have also been informed that Northland has voluntarily agreed to relinquish its Nomad status and will be removed from the register of Nomads with effect from 7am on 1 February 2019.

Furthermore, the Company recognises that Northland's merger with SP Angel remains subject to regulatory approvals and due diligence. In accordance with AIM Rule 1, if the Company fails to appoint a new Nomad by 1 February 2019 the Exchange will suspend trading in the Company's AIM Securities. If the Company has failed to appoint a replacement Nomad by 4 March 2019 the admission of its AIM Securities will be cancelled.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

Enquiries:

Polarean Imaging plc		www.polarean.com / www.polarean-ir.com
Richard Hullihen, Chief Executive Officer			Via Walbrook PR
Richard Morgan, Chairman
Northland Capital Partners Limited			Tel: +44 (0)20 3861 6625
David Hignell / Gerry Beaney / Jamie Spotswood (Corporate Finance) Rob Rees (Corporate Broking)
MC Services (European IR)			Tel: +49 (0)89 210 2280
Raimund Gabriel
The Life Sciences Division (Financial Adviser)
Navid Malik, Director			Mob: 07957 224 730
Alia Minhas, CEO			Mob: 07590 696 057
Walbrook PR	Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com
Paul McManus / Anna Dunphy Helen Cresswell	Mob: +44 (0)7980 541 893 / +44 (0)7879 741 001 +44 (0)7841 917 679

About Polarean (www.polarean.com)

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue generating, medical drug-device combination companies operating in the high resolution functional magnetic resonance imaging market.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

APPBRBDBBDGBGID